RxDoctor Payments Data

Faris Azzouni, MD

Urology · Hays, KSNPI 1619110608

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (33.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. Avyxa Pharma, LLC accounts for 65.2% of it on its own, with 10 other manufacturers making up the rest. 2025 is the largest year on record at $3,976, more than ten times the $148 reported in 2019.

$5,997in general payments, 2019–2025

Across 36 payments — averaging $166.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Avyxa Pharma, LLC$4K
  • Intuitive Surgical$2K
  • Sumitomo Pharma America, Inc.$203
  • Astellas Pharma US Inc$140
  • Urovant Sciences Inc$51
  • Medtronic$50
  • plus $143 from 5 others

What the payments were for

  • Speaking & faculty fees$2,00033%
  • Travel & lodging$1,63527%
  • Food & beverage$83914%
  • Education$1,52325%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,997 in reported general payments places this provider in the 70th percentile of 111 urology providers in Kansas.

See all urology providers in Kansas

Medicare billing

Part B allowed, 2024
$121,036
Medicare patients
240
Services billed
1,018

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron72$58,158
MyrbetriqMirabegron33$15,691
Methenamine Hippurate104$6,823
Silodosin37$4,045
Tamsulosin Hcl168$3,099
Finasteride182$2,869
Estradiol21$1,454
Oxybutynin Chloride ErOxybutynin Chloride50$1,005
Desmopressin Acetate14$888
Alfuzosin Hcl ErAlfuzosin Hcl20$573
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen42$263
Levofloxacin29$124
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim31$85

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$203$58,15872 claims
Astellas Pharma US IncMyrbetriq$140$15,69133 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 111 urology providers in Kansas.

Other urology in Hays

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →